Emergent BioSolutions Inc. (EBS) Financials

EBS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 1.1 billion 775.4 million
March 31, 2026 1.3 billion 797.3 million
Dec. 31, 2025 1.3 billion 796.0 million
Sept. 30, 2025 1.5 billion 878.5 million

EBS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -18.3 million 6.9 million
March 31, 2026 -36.2 million 1.9 million
Dec. 31, 2025 73.8 million 5.3 million
Sept. 30, 2025 -5.7 million 4.8 million

EBS Net Income

No data available :(

EBS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 139.7 million 581.8 million -
March 31, 2026 160.3 million 573.6 million -
Dec. 31, 2025 205.4 million 572.1 million -
Sept. 30, 2025 245.5 million 663.1 million -

EBS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 51.6 million
March 31, 2026 56.5 million
Dec. 31, 2025 52.4 million
Sept. 30, 2025 56.5 million

EBS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 2.1 million 9.2 million 44.6 million -
March 31, 2026 2.4 million 10.5 million 46.6 million -
Dec. 31, 2025 3.9 million 12.1 million 51.1 million -
Sept. 30, 2025 3.4 million 13.5 million 38.8 million -

EBS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 234.3 million 97.1 million
March 31, 2026 156.1 million 88.5 million
Dec. 31, 2025 148.7 million 102.1 million
Sept. 30, 2025 231.1 million 102.0 million

EBS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

EBS

Price: $6.38

52 week price:
4.36
14.06

Earnings Per Share: -3.15 USD

Exchange: NYQ

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 633400

Ebitda: 58.1 million

Market Capitalization: 364.8 million

Links: